SDX-7320

DRUG2 trials

Sponsors

SynDevRx, Inc., Memorial Sloan Kettering Cancer Center

Conditions

Advanced MalignancyAdvanced Solid TumorsBreast CancerMetastasisMetastatic Triple-Negative Breast CancerNeoplasm

Phase 1

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

CompletedNCT02743637

SynDevRx, Inc.Advanced Malignancy, Advanced Solid Tumors, Metastasis +1

Start: 2016-02-29End: 2019-12-16Updated: 2020-01-27

Phase 2

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

RecruitingNCT05570253

Memorial Sloan Kettering Cancer CenterBreast Cancer, Metastatic Triple-Negative Breast Cancer

Start: 2022-10-03End: 2027-10-01Target: 55Updated: 2026-09-09

Related Papers

Abstract PS5-02-23: Aretha trial: Safety run-in results of eribulin + evexomostat in metastatic triple-negative breast cancer with metabolic dysfunction

Clinical Cancer Research2026-02-17

Abstract B012: Anti-tumor activity of the METAP2 inhibitor evexomostat (SDX-7320) in multiple stage-specific models of prostate cancer, including treatment refractory and neuroendocrine (AVPC) phenotypes

Cancer Research2026-01-20

The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.

Journal of Clinical Oncology2023-06-011 citations

Abstract 1656: Evexomostat: A novel therapeutic in development for the treatment of prostate cancer

Cancer Research2023-04-04

Abstract P5-05-04: Inhibition of HER2+ tumor growth with SDX-7320, a novel MetAP2 inhibitor, alone and in combination with capivasertib/AZD-5363: Reduced expression of hypoxia-inducible and innate-immune system genes

Cancer Research2022-02-15

Abstract 1068: SDX-7320, a novel inhibitor of methionine aminopeptidase 2 (MetAP2), inhibits MCF-7 tumor growth in combination with palbociclib (Ibrance®)

Cancer Research2021-07-011 citations

Abstract P3-11-13: Synergistic inhibition of MCF-7 mammary gland tumor growth with Piqray® (alpelisib) plus SDX-7320, a novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor

Cancer Research2020-02-15

Abstract 1226: A novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor SDX-7320 inhibits the growth of EO771 mammary gland tumors and ameliorates the immunosuppressive tumor immune micro-environment (TIME)

Cancer Research2019-07-01

Abstract 1226: A novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor SDX-7320 inhibits the growth of EO771 mammary gland tumors and ameliorates the immunosuppressive tumor immune micro-environment (TIME)

Experimental and Molecular Therapeutics2019-07-01

Abstract 4919: Preclinical activity of SDX-7320 in mouse models of obesity and obesity-driven cancer

Cancer Research2018-07-01